Archive for the ‘Vasculitis’ Category

November 16, 2014

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

.   .   

In this RCT, patients with ANCA-associated vasculitis who achieved complete remission after a cyclophosphamide-glucocorticoid regimen were randomly assigned to receive intermittent rituximab (days 0 and 14 and at months 6, 12, and 18) or daily azathioprine until month 22.  Major relapse was less common in the rituximab arm than the azathioprine arm (5% vs 29%) […]

Comments Off on Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis Posted in Vasculitis
December 21, 2013

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

.   .   

This randomized trial compared rituximab with cyclophosphamide followed by azathioprine in severe ANCA-associated vasculitis. This noninferiority trial showed that there was no difference at 18 months for the induction and maintenance of remissions between groups.

Comments Off on Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis Posted in Clinical Nephrology, Clinical Trial Results, Glomerulonephritis, Vasculitis
November 29, 2011

Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis

.   .   

This study of twenty-three patients presenting or relapsing with ANCA-associated vasculitis were treated with two pulses of rituximab 2 weeks apart, six biweekly doses of cyclophosphamide and a tapering course of oral steroids. They were subsequently put on a maintenance regimen of low-dose steroids and azathioprine.  All patients achieved clinical remission within six weeks. Five […]

Comments Off on Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis Posted in Vasculitis
June 14, 2011

Maintenance Immunosuppression in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

.   .   

This review provides commentary on the article ‘Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.’, authored by Hiemstra TF, Walsh M, Mahr A, et al for the European Vasculitis Study Group (EUVAS).

Comments Off on Maintenance Immunosuppression in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Posted in Review, Vasculitis
November 8, 2010

Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Trial

In this publication by the EUVAS group, mycophenolate mofetil was found to be less effective than azathioprine for maintaining disease remission in ANCA-associated vasculitis. Free full text provided by JAMA.

Comments Off on Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Trial Posted in Vasculitis
November 8, 2010

Therapeutic Interventions for Systemic Vasculitis

This editorial provides critical analysis and commentary on the article ‘Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Trial’. Free full text provided by JAMA.

Comments Off on Therapeutic Interventions for Systemic Vasculitis Posted in Editorial, Vasculitis
July 20, 2010

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

.   .   

This RCT did not find that a rituximab-based regimen was superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis.

Comments Off on Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis Posted in Acute Kidney Injury, Vasculitis
July 20, 2010

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

.   .   

This non-inferiority trial finds that rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. See the associated editorial.

Comments Off on Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis Posted in Acute Kidney Injury, Vasculitis
May 2, 2009

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.

.   .   

This randomized controlled trial compared pulse versus oral cyclophosphamide for induction in ANCA vasculitis. No difference in efficacy was detected between the two arms but pulse treatment resulted in a reduced cumulative cyclophosphamide dose and caused fewer cases of leukopenia.

Comments Off on Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis. Posted in Vasculitis
May 1, 2009

Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?

.   .   

Comments Off on Vasculitis syndromes: which maintenance therapy for ANCA vasculitis? Posted in Review, Vasculitis
April 1, 2009

Review article: Progress of treatment in ANCA-associated vasculitis.

.   .   

Comments Off on Review article: Progress of treatment in ANCA-associated vasculitis. Posted in Vasculitis
July 1, 2008

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

.   .   

Comments Off on Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Posted in Vasculitis
July 1, 2008

Treatment for renal vasculitis and Goodpasture’s disease in adults.

.   .   

Comments Off on Treatment for renal vasculitis and Goodpasture’s disease in adults. Posted in Vasculitis